Guardant Health is targeting $100m in proceeds for its initial public offering on the Nasdaq Global Select Market, which would offer an exit to SoftBank.
Guardant Health, a US-based developer of a liquid biopsy system for cancer detection backed by telecoms and internet conglomerate SoftBank, has filed for a $100m initial public offering on the Nasdaq Global Select Market.
Founded in 2013, Guardant is developing non-invasive cancer diagnostics tests for cancer that rely on blood tests, data analytics and large data sets to identify genomic alterations that cause cancerous tumours to grow, evolve, become resistant to treatment or recur.
Guardant has launched two tests…
